sitem-insel AG

Blankart, C., R., A. Foster, & V. Mor 2018. The Effect of Political Control on Financial Performance, Structure, and Outcomes of US Nursing Homes. Health Services Research, accepted.

Dams, F., J. L. Gonzalez Rodriguez, K. L. Cheung, B. F. Wijnen, & M. Hiligsmann 2018. Relevance of barriers and facilitators in the use of health technology assessment in Colombia. Journal of medical economics, 21(5), 510-517. DOI: 10.1080/13696998.2018.1449751.

Blankart, C., R., A. Foster, & V. Mor 2017. The Effect of Political Control on Financial Performance and Structure of US Nursing Homes. Acad Manage Proc 2017. DOI: 10.5465/ambpp.2017.7.

Hatz, M. H. M., Sonnenschein, T., & Blankart, C. R. 2017. The PMA Scale: A Measure of Physicians’ Motivation to Adopt Medical Devices. Value in Health, 20(4): 533-541. DOI: 10.1016/j.jval.2016.12.002.

Varabyova, Y., Blankart, C. R., Greer, A. L., & Schreyögg, J. 2017. The determinants of medical technology adoption in different decisional systems: A systematic literature review. Health Policy, 121(3): 230-242.    DOI: 10.1016/j.healthpol.2017.01.005.

Hatz, M. H. M., Schreyögg, J., Torbica, A., Boriani, G., & Blankart, C. R. B. 2017. Adoption Decisions for Medical Devices in the Field of Cardiology: Results from a European Survey. Health Economics, 26(S1): 124-144. DOI: 10.1002/hec.3472.

Varabyova, Y., Blankart, C. R., & Schreyögg, J. 2017. The Role of Learning in Health Technology Assessments: An Empirical Assessment of Endovascular Aneurysm Repairs in German Hospitals. Health Economics, 26(S1): 93-108.    DOI: 10.1002/hec.3466.

Sachweh, A., von Kodolitsch, Y., Kölbel, T., Larena-Avellaneda, A., Wipper, S., Bernhardt, A. M., Girdauskas, E., Detter, C., Reichenspurner, H., Blankart, C. R., & Debus, E. S. 2017. I-SWOT as instrument to individually optimize therapy of thoracoabdominal aortic aneurysms. Gefässchirurgie, 22(1): 8-16.    DOI: 10.1007/s00772-017-0245-z.

Varabyova, Y., Blankart, C. R., & Schreyögg, J. 2017. Using nonparametric conditional approach to integrate quality into efficiency analysis: empirical evidence from cardiology departments. Health Care Manag Sci, 20(4): 565-576. DOI: 10.1007/s10729-016-9372-4.

Varabyova, Y., Blankart, C. R., & Schreyögg, J. 2017. Erratum to: Using nonparametric conditional approach to integrate quality into efficiency analysis: empirical evidence from cardiology departments. Health Care Manag Sci, 20(4): 577. DOI: 10.1007/s10729-016-9391-1.

Blankart, C. R., & Stargardt, T. 2017. Preferred supplier contracts in post-patent prescription drug markets. Health Care Manag Sci, 20(3): 419-432.  DOI: 10.1007/s10729-016-9362-6.

Varabyova, Y., Blankart, C. R., Torbica, A., & Schreyögg, J. 2017. Comparing the Efficiency of Hospitals in Italy and Germany: Nonparametric Conditional Approach Based on Partial Frontier. Health Care Manag Sci, 20(3): 379-394.  DOI: 10.1007/s10729-016-9359-1.

Schlage, V., & Blankart, C. R. 2016. Does Direct-care Staffing Impact Nursing Home Outcomes? A Systematic Review. Die Unternehmung, 70(3): 291-318. DOI: 10.5771/0042-059X-2016-3-291.

Blankart, C. R., Emanuel, E. J., Bekelman, J. E., & International Consortium for End-of-Life, R. 2016. Characteristics of Patients Dying With Cancer in Developed Countries--Reply. JAMA, 315(24): 2732. DOI: 10.1001/jama.2016.4042.

Blankart, C. R., Milstein, R., Rybczynski, M., Schüler, H., & von Kodolitsch, Y. 2016. Economic and care considerations of Marfan syndrome. Expert Review of Pharmacoeconomics & Outcomes Research, 16(5): 591-598.  DOI: 10.1080/14737167.2016.1240619.

Milstein, R., & Blankart, C. R. 2016. The Health Care Strengthening Act: the next level of integrated care in Germany. Health Policy, 120(5): 445-451.    DOI: 10.1016/j.healthpol.2016.04.006.

Bekelman, J. E., Halpern, S. D., Blankart, C. R., Bynum, J. P., Cohen, J., Fowler, R., Kaasa, S., Kwietniewski, L., Melberg, H. O., Onwuteaka-Philipsen, B., Oosterveld-Vlug, M., Pring, A., Schreyögg, J., Ulrich, C. M., Verne, J., Wunsch, H., Emanuel, E. J., & International Consortium for End-of-Life, R. 2016. Comparison of Site of Death, Health Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in 7 Developed Countries. JAMA, 315(3): 272-283.  DOI: 10.1001/jama.2015.18603.

Frey, S., Blankart, C. R., & Stargardt, T. 2016. Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature. Pharmacoeconomics, 34(5): 479-498. DOI: 10.1007/s40273-015-0367-7.

von Kodolitsch, Y., Blankart, C. R., Vogler, M., Kallenbach, K., & Robinson, P. N. 2015. [Genetics and prevention of genetic aortic syndromes (GAS) and of the Marfan syndrome]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 58(2): 146-153. DOI: 10.1007/s00103-014-2093-2.

Ciani, O., Wilcher, B., Blankart, C. R., Hatz, M., Rupel, V. P., Erker, R. S., Varabyova, Y., & Taylor, R. S. 2015. Health technology assessment of medical devices: a survey of non-European union agencies. Int J Technol Assess Health Care, 31(3): 154-165. DOI: 10.1017/S0266462315000185.

Achelrod, D., Blankart, C. R., Linder, R., von Kodolitsch, Y., & Stargardt, T. 2014. The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study. Orphanet J Rare Dis, 9: 90.  DOI: 10.1186/1750-1172-9-90.

Blankart, C. R., Koch, T., Linder, R., Verheyen, F., Schreyögg, J., & Stargardt, T. 2013. Cost of illness and economic burden of chronic lymphocytic leukemia. Orphanet J Rare Dis, 8: 32. DOI: 10.1186/1750-1172-8-32.

Blankart, C. R. 2012. Does healthcare infrastructure have an impact on delay in diagnosis and survival? Health Policy, 105(2-3): 128-137.  DOI: 10.1016/j.healthpol.2012.01.006.

Blankart, C. R., Stargardt, T., & Schreyögg, J. 2011. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia. Pharmacoeconomics, 29(1): 63-82.  DOI: 10.2165/11539190-000000000-00000.

Blankart, R., Schreyögg, J., & Busse, R. 2008. Performance of reimbursement schemes in valuation of technologies: the example of magnetic resonance imaging. Technol Health Care, 16(3): 171-182.